Skip to Content

Generic Dilaudid-HP Availability

See also: Generic Dilaudid

Dilaudid-HP is a brand name of hydromorphone, approved by the FDA in the following formulation(s):

DILAUDID-HP (hydromorphone hydrochloride - injectable;injection)

  • Manufacturer: FRESENIUS KABI USA
    Approval date: January 11, 1984
    Strength(s): 10MG/ML [RLD]
  • Manufacturer: FRESENIUS KABI USA
    Approval date: August 4, 1994
    Strength(s): 250MG/VIAL

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dilaudid-HP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Hydromorphone and hydrocodone compositions and methods for their synthesis
    Patent 6,589,960
    Issued: July 8, 2003
    Inventor(s): William H.; Harclerode & Robert; Gault & Mark D.; Sandison
    Assignee(s): Abbott Laboratories

    A method for the preparation of a ketone from a narcotic alkaloid having an allyl alcohol moiety is disclosed. The method includes mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. The method is useful for preparing hydromorphone and hydrocodone compositions having novel impurity profiles. Compositions comprising hydromorphone and hydrocodone are also disclosed.

    Patent expiration dates:

    • November 9, 2020
      Drug product
  • Packaging system for oxygen-sensitive drugs
    Patent 9,248,229
    Issued: February 2, 2016
    Assignee(s): Becton, Dickinson France S.A.S.

    Described herein are pharmaceutical packaging systems which prevent oxidative degradation of morphine, hydromorphone, promethazine and other oxygen-sensitive drugs, such systems including a syringe with an oxygen permeable tip cap, a hermetically sealed oxygen barrier blister packaging with very low permeability to oxygen and comprises ethylene vinyl, and an oxygen absorber.

    Patent expiration dates:

    • March 12, 2034
      Drug product
  • Drug container
    Patent 9,731,082
    Issued: August 15, 2017
    Assignee(s): Fresenius Kabi Deutschland GmbH

    The present invention relates to an assembly (101) comprising: an injection device (1) comprising a container (2) for a product, said container comprising a distal tip (3), an adaptor (5) comprising a ring (6) mounted onto said distal tip (3), characterized in that said assembly (101) further comprises a heat-shrinkable film (9) covering part (2a) of said container (2) and part (5a) of said adaptor (5), said film (9) maintaining said adaptor (5) blocked in rotation and in translation with respect to said container (2) when said film (9) is in its heat-shrunk condition. The invention further relates to a method for manufacturing such an assembly.

    Patent expiration dates:

    • April 23, 2032
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.